DRDO’s anti-Covid drug 2-DG to be available at hospitals from June

The drug, named 2-deoxy-D-glucose (2-DG), has been developed jointly by Institute of Nuclear Medicine and Allied Sciences, a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories, Hyderabad.

The Drugs Controller General of India (DCGI) earlier this month granted permission for emergency use of the drug as an adjunct therapy in moderate to severe Covid patients.

The Defence Research and Development Organisation’s 2-deoxy-D-glucose or ‘2-DG’ drug is the latest indigenous addition to India’s Covid-19 management efforts.

On May 1, the Drugs Controller General of India (DCGI) had cleared the formulation for emergency use as an adjunct therapy in moderate to severe Covid patients and the first batch of the homegrown anti-Covid drug was released on May 17 in the presence of Defence Minister Rajnath Singh and Health Minister Dr Harsh Vardhan.

The 2-DG has been developed by DRDO’s Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Hyderabad-based pharmaceutical giant Dr Reddy’s Laboratories (DRL).  

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.